×
About 2,308 results

ALLMedicine™ Apraxia Center

Research & Reviews  839 results

De novo heterozygous variants in SLC30A7 are a candidate cause for Joubert syndrome.
https://doi.org/10.1002/ajmg.a.62872
American Journal of Medical Genetics. Part A; Penon-Portmann M, Eldomery MK et. al.

Jun 26th, 2022 - Joubert syndrome (JS), a well-established ciliopathy, is characterized by the distinctive molar tooth sign on brain MRI, ataxia, and neurodevelopmental features. Other manifestations can include polydactyly, accessory frenula, renal, or liver dise...

Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing
https://clinicaltrials.gov/ct2/show/NCT04394871

Jun 24th, 2022 - Objective: Amyotrophic lateral sclerosis type 4 (ALS4) is an inherited form of motor neuron disease caused by mutation in the senataxin (SETX) gene. The main goal of this study will be to collect clinical and molecular biomarkers from patients wit...

Gait apraxia evaluation in normal pressure hydrocephalus using inertial sensors. Clinic...
https://doi.org/10.1186/s12987-022-00350-y 10.1016/0022-510X(65)90016-X 10.1016/j.clineuro.2019.105385 10.1016/j.jns.2019.05.029 10.1016/j.parkreldis.2018.02.024 10.1093/neurosurgery/24.CN_suppl_1.270 10.1093/brain/83.2.261 10.1007/s00701-013-1835-5 10.1177/0269215518760126 10.1111/j.1468-1331.2011.03486.x 10.1016/j.apmr.2018.03.018 10.1016/j.jns.2016.01.028 10.1016/j.apmr.2015.02.014 10.1016/j.parkreldis.2019.07.021 10.1186/s12984-019-0638-1 10.1016/j.clineuro.2020.106402 10.3390/s140203362 10.1109/TNSRE.2015.2457511 10.3389/fneur.2021.635044 10.1016/S1388-2457(00)00362-X 10.1016/j.clineuro.2017.06.001 10.1016/j.gaitpost.2019.05.017 10.1097/PHM.0b013e31815b6461 10.1038/s41598-019-52448-3 10.4324/9780203771587 10.1111/j.1532-5415.1986.tb05480.x 10.1159/000111149 10.1136/jnnp.73.6.721 10.1016/0003-9993(94)90384-0 10.1161/STROKEAHA.117.017866 10.3390/s140406229 10.1016/S0895-4356(02)00482-1 10.1037/0033-2909.86.2.420 10.1111/j.1467-985X.2007.00509.x 10.1186/s41512-018-0037-2 10.3109/09638288.2014.961661 10.1093/ptj/86.7.944 10.1109/TBME.2012.2216263 10.1007/s00221-007-0955-7
Fluids and Barriers of the CNS; Ferrari A, Milletti D et. al.

Jun 24th, 2022 - Idiopathic normal pressure hydrocephalus (iNPH) is a neurological condition with gait apraxia signs from its early manifestation. Ventriculoperitoneal shunt (VPS) is a surgical procedure available for treatment. The Cerebrospinal fluid Tap Test (C...

AAC barriers and facilitators for children with Koolen de Vries syndrome and childhood ...
https://doi.org/10.1080/07434618.2022.2085626
Augmentative and Alternative Communication (Baltimore, Md... Johnston SS, Blue CW et. al.

Jun 22nd, 2022 - Despite the potential positive impact of augmentative and alternative communication, the literature suggests that many individuals with disabilities experience barriers in developing communication skills and access to appropriate supports. Parents...

Effects of tDCS on Apraxia of Speech in Non-Fluent Primary Progressive Aphasia
https://clinicaltrials.gov/ct2/show/NCT04486586

Jun 15th, 2022 - A. Evaluation Tasks Language Tasks: Participants will be administered baseline language and cognitive tasks, including 1 or more of the following, depending on participants' residual language and cognitive skills: a) writing to dictation b) oral s...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  63 results

Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing
https://clinicaltrials.gov/ct2/show/NCT04394871

Jun 24th, 2022 - Objective: Amyotrophic lateral sclerosis type 4 (ALS4) is an inherited form of motor neuron disease caused by mutation in the senataxin (SETX) gene. The main goal of this study will be to collect clinical and molecular biomarkers from patients wit...

Effects of tDCS on Apraxia of Speech in Non-Fluent Primary Progressive Aphasia
https://clinicaltrials.gov/ct2/show/NCT04486586

Jun 15th, 2022 - A. Evaluation Tasks Language Tasks: Participants will be administered baseline language and cognitive tasks, including 1 or more of the following, depending on participants' residual language and cognitive skills: a) writing to dictation b) oral s...

Changes in Sensitivity, Taste and Smell in Stroke Patients
https://clinicaltrials.gov/ct2/show/NCT03240965

Jun 14th, 2022 - Stroke is the second leading cause of death. At least 50% of stroke patients develop dysphagia, leading to aspiration pneumonia, which is the main cause of death in stroke [2]. It is assumed that normal sensitivity is vital for aspiration-free swa...

Rehabilitating (Stroke-induced) Apraxia With Direct Current Stimulation
https://clinicaltrials.gov/ct2/show/NCT03185234

May 20th, 2022 - Despite the high incidence of the motor cognitive deficit apraxia after left-hemispheric stroke, evidence-based therapies do not exist. This randomized controlled clinical trial (RCT) investigates whether anodal transcranial direct current stimula...

Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation
https://clinicaltrials.gov/ct2/show/NCT05368350

May 10th, 2022 - This pilot study has one treatment arm with open-label treatment and will examine improvement of speech output, verbal fluency, and other cognitive deficits associated with primary progressive aphasia (PPA) and progressive apraxia of speech (PAOS)...

see more →

News  14 results

Inhaled Heroin Tied to 'Peculiar, Often Catastrophic' Brain Damage
https://www.medscape.com/viewarticle/899079

Jul 9th, 2018 - "Chasing the dragon" (CTD) — a method of inhaling heroin in which users heat heroin over aluminium foil with a lighter and then chase the fumes — is growing in popularity and may lead to "peculiar and often catastrophic brain complications," new r...

Can Botulinum Toxin Benefit People With Parkinson’s Disease?
https://www.mdedge.com/neurology/article/136563/parkinsons-disease/can-botulinum-toxin-benefit-people-parkinsons-disease

Apr 25th, 2017 - Robert Chen, MBBChir MIAMI—Botulinum toxin may be a clinically useful treatment for motor and nonmotor manifestations of Parkinson’s disease and parkinsonism, according to an overview presented at the First Pan American Parkinson’s Disease and Mov.

Alemtuzumab Linked to CNS Inflammation
https://www.medscape.com/viewarticle/875002

Jan 26th, 2017 - Two cases of what is suggested to be "the first recognised cases of severely exacerbated CNS [central nervous system] inflammation after alemtuzumab therapy in multiple sclerosis" have been published. Writing in a letter in the February issue of T...

Experts review challenges, pearls in young onset dementia
https://www.mdedge.com/psychiatry/article/113800/alzheimers-cognition/experts-review-challenges-pearls-young-onset-dementia
Amy Karon

Sep 19th, 2016 - SAN FRANCISCO – The patient, a man in his early 50s, smiled as he sang about flatulence. He seemed alert, relaxed, and aware of his wife and the neurologist in the room.

see more →

Patient Education  6 results see all →